Edition:
United States

BioDelivery Sciences International Inc (BDSI.OQ)

BDSI.OQ on NASDAQ Stock Exchange Capital Market

2.70USD
20 Sep 2017
Change (% chg)

$-0.03 (-0.92%)
Prev Close
$2.72
Open
$2.75
Day's High
$2.75
Day's Low
$2.70
Volume
50,702
Avg. Vol
79,135
52-wk High
$3.60
52-wk Low
$1.55

Chart for

About

BioDelivery Sciences International, Inc. is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products... (more)

Overall

Beta: 0.98
Market Cap(Mil.): $151.17
Shares Outstanding(Mil.): 55.48
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.91 16.25
EPS (TTM): -- -- --
ROI: -- 15.14 14.87
ROE: -- 16.37 13.89

BRIEF-BioDelivery Sciences CEO Mark Sirgo to retire

* BioDelivery Sciences president and chief executive officer Mark Sirgo to retire at year-end while continuing as vice chairman

Aug 23 2017

BRIEF-BioDelivery Sciences reports Q2 loss per share $0.27

* BioDelivery Sciences reports second quarter 2017 financial results and provides corporate update

Aug 09 2017

BRIEF-Biodelivery Sciences signs agreement with Purdue Pharma

* Biodelivery Sciences signs exclusive agreement with Purdue Pharma (Canada) for the licensing and distribution rights of Belbuca in Canada

Jul 12 2017

BRIEF-Biodelivery Sciences announces Health Canada approval of Belbuca

* Biodelivery Sciences announces Health Canada approval of Belbuca®

Jun 23 2017

BRIEF-BioDelivery Sciences announces agreement with CVS/Caremark for Belbuca, Bunavail

* BioDelivery Sciences announces agreement with CVS/Caremark for Belbuca® and Bunavail® through 2020

Jun 21 2017

BRIEF-Biodelivery Sciences Q1 earnings per share $0.87

* Biodelivery Sciences International Inc - net revenue for Q1 ended March 31, 2017, was approximately $29.5 million.

May 15 2017

BRIEF-Biodelivery Sciences International files for non-timely 10-Q - SEC Filing

* Biodelivery Sciences International Inc says requires up to five additional days to file form 10-Q for the fiscal quarter ended March 31, 2017

May 10 2017

BRIEF-BioDelivery Sciences announces approval of BUNAVAIL

* Biodelivery sciences announces the approval of bunavail® for induction of buprenorphine treatment for opioid dependence

May 02 2017

BRIEF-Biodelivery Sciences announces the granting of two new patents

March 31 Biodelivery Sciences International Inc :

Mar 31 2017

Earnings vs. Estimates